S. Boulton

发表

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

R. Coleman, R. McLendon, A. Friedman, 2008, Neuro-oncology.

Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.

R. McLendon, A. Friedman, D. Bigner, 2007, Nuclear medicine and biology.

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

E. Lipp, H. Friedman, D. Reardon, 2012, Journal of Neuro-Oncology.

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

A. Friedman, E. Lipp, H. Friedman, 2012, British Journal of Cancer.

Molecular Targets for Antibody-Mediated Immunotherapy of Malignant Glioma

D. Bigner, D. Reardon, C. Kuan, 2009 .

A cross sectional analysis from a single institution’s experience of psychosocial distress and health-related quality of life in the primary brain tumor population

S. Keir, E. Lipp, H. Friedman, 2017, Journal of Neuro-Oncology.

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.

A. Friedman, D. Bigner, E. Lipp, 2015 .

Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.

E. Lipp, H. Friedman, A. Desjardins, 2019, Complementary therapies in clinical practice.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).

A. Friedman, D. Bigner, H. Friedman, 2014 .

Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.

A. Friedman, D. Bigner, E. Lipp, 2016 .